Verona to raise £14m to go it alone in niche COPD indication
This article was originally published in Scrip
UK-based Verona Pharma plans to raise £14m, which the company believes will be enough to complete several clinical trials with its lead COPD candidate, RPL554. The fundraising is part of the company's plan to commercialize the drug without a partner in a niche hospital setting.
You may also be interested in...
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.